Cocrystal Pharma, Inc.

NasdaqCM COCP

Cocrystal Pharma, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2024: 10,174,000

Cocrystal Pharma, Inc. Shares (Diluted, Weighted) is 10,174,000 for the Trailing 12 Months (TTM) ending September 30, 2024, a 11.48% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Cocrystal Pharma, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2023 was 9,126,000, a 15.36% change year over year.
Cocrystal Pharma, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2022 was 7,910,895, a 21.09% change year over year.
Cocrystal Pharma, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2021 was 6,533,082.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NasdaqCM: COCP

Cocrystal Pharma, Inc.

CEO	Dr. Sam Lee Ph.D.
IPO Date	Feb. 22, 2012
Location	United States
Headquarters	19805 North Creek Parkway
Employees	12
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.

Key trends

Past 5 years